Maratta, M.G.; Sparagna, I.; Occhipinti, D.; Roca, L.; Sgambato, M.; Raia, S.; Bianchi, A.; Chiloiro, S.; Rossi, E.; Rindi, G.;
et al. Upfront Oxaliplatin–Fluoropyrimidine Chemotherapy and Somatostatin Analogues in Advanced Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors. Cancers 2025, 17, 1561.
https://doi.org/10.3390/cancers17091561
AMA Style
Maratta MG, Sparagna I, Occhipinti D, Roca L, Sgambato M, Raia S, Bianchi A, Chiloiro S, Rossi E, Rindi G,
et al. Upfront Oxaliplatin–Fluoropyrimidine Chemotherapy and Somatostatin Analogues in Advanced Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors. Cancers. 2025; 17(9):1561.
https://doi.org/10.3390/cancers17091561
Chicago/Turabian Style
Maratta, Maria Grazia, Ileana Sparagna, Denis Occhipinti, Luigi Roca, Margherita Sgambato, Salvatore Raia, Antonio Bianchi, Sabrina Chiloiro, Ernesto Rossi, Guido Rindi,
and et al. 2025. "Upfront Oxaliplatin–Fluoropyrimidine Chemotherapy and Somatostatin Analogues in Advanced Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors" Cancers 17, no. 9: 1561.
https://doi.org/10.3390/cancers17091561
APA Style
Maratta, M. G., Sparagna, I., Occhipinti, D., Roca, L., Sgambato, M., Raia, S., Bianchi, A., Chiloiro, S., Rossi, E., Rindi, G., Tortora, G., & Schinzari, G.
(2025). Upfront Oxaliplatin–Fluoropyrimidine Chemotherapy and Somatostatin Analogues in Advanced Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors. Cancers, 17(9), 1561.
https://doi.org/10.3390/cancers17091561
